Lincoln Pharma Q3FY2016 Investors & Business Presentation

“We are pleased to announce a stellar performance with over 40% growth in our revenue during the nine months of the fiscal year. Our growth was broad-based across all the therapeutic areas. Of the total sales during the nine months, around 29% was contributed by exports business. The profitability during the period ended December 2015 included the benefit from fuel cost savings on account of commissioning of wind mill during the fiscal year. Various strategic initiatives undertaken during the year coupled with operational efficiencies is expected to pave way for our future topline growth as well as further enhancement of profitability.” Mr. Mahendra G. Patel, Managing Director

2015-16-Q3-Business-Presentation